To achieve a patient-centered transformation initiative, it’s important to navigate the change process with rigor, using evidence-based approaches and integrating behavioral sciences. Here are a few key lessons learned from multiple patient-centric transformations.
The practices, processes, and tools of the user experience (UX) design community, which has been conducting at-home research with users for many years, could help address some of the new challenges associated with remote and hybrid clinical trials.
“Decentralized and hybrid trials offer convenience, but that convenience must be balanced with individual preferences. We are entering an age of more personalized and customized participant experiences, and we have to figure out how to manage that,” says Ken Getz of CISCRP.
Two Janssen execs talk about the future of what they call a pathway approach to developing new medicines, which attempts to match the biology of a pathway to unmet medical need for patients, across a broad range of immune-mediated, inflammatory disease.
This is an exciting time to be involved in clinical trials. I feel like I have been saying that for the more than eight years that I have been writing about clinical research, and every year seems to bring new technologies and new opportunities.
During the last year, despite countless obstacles and dangers, the pharma industry managed to remain steadfast and get to where we are today – hopefully with COVID-19 in the rear-view mirror. Let’s take a closer look at the numbers.
Advancements in AI and machine learning (ML) for data collection and interpretation could increase the threat of cyber-attacks and malicious hacking of private medical data. As such, sponsors shouldn’t overlook the liability risk of such advancements and the corresponding changes that should be made to business insurance.
Many biopharmas still find it difficult to make sharing and using external trial data routine. How do we build on new momentum to continue and accelerate the use of historical trial data to transform R&D in the future?